Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous Close | 1.2500 |
| Open | 1.0400 |
| Bid | 1.0600 x 800 |
| Ask | 1.1400 x 800 |
| Day's Range | 1.0308 - 1.1400 |
| 52 Week Range | 1.0300 - 2.5100 |
| Volume | |
| Avg. Volume | 426,090 |
| Market Cap | 80.648M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 12.22 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript May 10, 2024 Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business […]
- Insider Monkey
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- GuruFocus.com
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
